Altamira Therapeutics Ltd. (EARS) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Altamira Therapeutics Ltd...

    NASDAQ: EARS · Real-Time Price · USD
    3.04
    -0.06 (-1.94%)
    At close: Jul 26, 2021, 6:00 AM

    Altamira Therapeutics Income Statement

    Financials in CHF. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 305.62K 63.88K
    Cost of Revenue
    		 n/a 1.44M 2.24M
    Gross Profit
    		 n/a -1.14M -2.18M
    Operating Income
    		 -5.92M -18.01M -5.34M
    Interest Income
    		 730.2K 114.27K 26.99K
    Pretax Income
    		 -7.27M -18.66M -6.81M
    Net Income
    		 -7.27M -26.53M -17.06M
    Selling & General & Admin
    		 3.12M 3.39M 3.62M
    Research & Development
    		 3.04M 14.62M 3.2M
    Other Expenses
    		 n/a 112.67K 30.43K
    Operating Expenses
    		 6.54M 18.01M 6.87M
    Interest Expense
    		 n/a 911.87K 14.11K
    Selling & Marketing Expenses
    		 15.35K 15.73K 39.92K
    Cost & Expenses
    		 6.54M 18.01M 6.87M
    Income Tax Expense
    		 n/a -10.33K -117.94K
    Shares Outstanding (Basic)
    		 491K 45.54K 33.12K
    Shares Outstanding (Diluted)
    		 491.26K 45.54K 33.12K
    EPS (Basic)
    		 -14.81 -582.58 -515.11
    EPS (Diluted)
    		 -14.8 -582.58 -515.11
    EBITDA
    		 -1.35M -17.64M -6.72M
    EBIT
    		 n/a -17.75M -6.79M
    Depreciation & Amortization
    		 5.92M 118.89K 76.36K

    Add to Watchlist